Article
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
International journal of hematology - 1 Feb 2014
Fujisawa Shin, Nakamae Hirohisa, Ogura Michinori, Ishizawa Ken-ichi, Taniwaki Masafumi, Utsunomiya Atae, Matsue Kosei, Takamatsu Yasushi, Usuki Kensuke, Tanimoto Mitsune, Ishida Yoji, Akiyama Hideki, Onishi Shintaro
Abstract excerpt
Dasatinib is a highly potent BCR-ABL kinase inhibitor with established efficacy and safety in imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. In the global phase III DASISION trial in patients with newly diagnosed chronic phase CML (CML-CP), dasatinib was found to have an acceptable safety profile and demonstrated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.